{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:23:02Z","timestamp":1760235782221,"version":"build-2065373602"},"reference-count":163,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["2017WXR7ZT"],"award-info":[{"award-number":["2017WXR7ZT"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) started in December 2019 in China and then become pandemic in February 2020. Several publications investigated the possible increased rate of COVID-19 infection in hematological malignancies. Based on the published data, strategies for the management of chronic Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are provided. The risk of severe COVID-19 seems high in MPN, particularly in patients with essential thrombocythemia, but not negligible in myelofibrosis. MPN patients are at high risk of both thrombotic and hemorrhagic complications and this must be accounted in the case of COVID-19 deciding on a case-by-case basis. There are currently no data to suggest that hydroxyurea or interferon may influence the risk or severity of COVID-19 infection. Conversely, while the immunosuppressive activity of ruxolitinib might pose increased risk of infection, its abrupt discontinuation during COVID-19 syndrome is associated with worse outcome. All MPN patients should receive vaccine against COVID-19; reassuring data are available on efficacy of mRNA vaccines in MPNs.<\/jats:p>","DOI":"10.3390\/cancers13194750","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T09:59:15Z","timestamp":1632391155000},"page":"4750","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia \u201cSer\u00e0gnoli\u201d, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University, 00185 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University School of Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Host Factors in Coronavirus Replication","volume":"419","author":"Snijder","year":"2018","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/JVI.02605-06","article-title":"Evolutionary insights into the ecology of coronaviruses","volume":"81","author":"Vijaykrishna","year":"2007","journal-title":"J. Virol."},{"key":"ref_3","first-page":"523","article-title":"SARS and MERS: Recent insights into emerging coronaviruses. Nature reviews","volume":"14","author":"Falzarano","year":"2016","journal-title":"Microbiology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus Infections-More Than Just the Common Cold","volume":"323","author":"Paules","year":"2020","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","volume":"63","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical Characteristics of Coronavirus Disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/rth2.12372","article-title":"A proposal for staging COVID-19 coagulopathy","volume":"4","author":"Thachil","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(20)30673-5","article-title":"COVID-19: Towards controlling of a pandemic","volume":"395","author":"Bedford","year":"2020","journal-title":"Lancet"},{"key":"ref_10","unstructured":"Johns Hopkins University (2021, May 18). COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: https:\/\/gisanddata.maps.arcgis.com\/apps\/opsdashboard\/index.html#\/bda7594740fd40299423467b40299423448e40299423469ecf40299423466."},{"key":"ref_11","first-page":"335","article-title":"Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. The Lancet","volume":"21","author":"Liang","year":"2020","journal-title":"Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S1470-2045(20)30150-9","article-title":"Risk of COVID-19 for patients with cancer","volume":"21","author":"Xia","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(20)30149-2","article-title":"Risk of COVID-19 for patients with cancer","volume":"21","author":"Wang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/00368504211000906","article-title":"Comparison of clinical manifestations, pre-existing comorbidities, complications and treatment modalities in severe and non-severe COVID-19 patients: A systemic review and meta-analysis","volume":"104","author":"Giri","year":"2021","journal-title":"Sci. Prog."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.24572","article-title":"Risk factors for infections in myelofibrosis: Role of disease status and treatment. A multicenter study of 507 patients","volume":"92","author":"Polverelli","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and Cause of Death in Patients Diagnosed with Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1097-0142(19890901)64:5<1038::AID-CNCR2820640513>3.0.CO;2-W","article-title":"Decreased natural killer (NK) activity in patients with myeloproliferative disorders","volume":"64","author":"Froom","year":"1989","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1034\/j.1600-0609.2000.90262.x","article-title":"Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis","volume":"65","author":"Cervantes","year":"2000","journal-title":"Eur. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1521-6616(02)00046-3","article-title":"Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis","volume":"106","author":"Briard","year":"2003","journal-title":"Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An immune dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wang, J.C., Sindhu, H., Chen, C., Kundra, A., Kafeel, M.I., Wong, C., and Lichter, S. (2015). Immune derangements in patients with myelofibrosis: The role of Treg, Th17, and sIL2R\u03b1. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0116723"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41375-020-0909-7","article-title":"Risk of infections in patients with myeloproliferative neoplasms-a population-based cohort study of 8363 patients","volume":"35","author":"Landtblom","year":"2021","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: A systematic review and meta-analysis","volume":"93","author":"Lussana","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/bjh.13373","article-title":"JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms","volume":"169","author":"Cornez","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms","volume":"75","author":"Rudolph","year":"2015","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjh.13519","article-title":"JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells","volume":"171","author":"Keohane","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2016.155","article-title":"The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK","volume":"30","author":"Rudolph","year":"2016","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","article-title":"Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib","volume":"28","author":"Massa","year":"2014","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1071009","DOI":"10.1080\/2162402X.2015.1071009","article-title":"Get a grip on immune cells by inhibiting JAKs","volume":"5","author":"Rudolph","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1782575","DOI":"10.1080\/2162402X.2020.1782575","article-title":"The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis","volume":"9","author":"Barone","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chen, C.X., Wang, J.J., Li, H., Yuan, L.T., Gale, R.P., and Liang, Y. (2021). JAK-inhibitors for coronavirus disease-2019 (COVID-19): A meta-analysis. Leukemia, 1\u20135.","DOI":"10.1038\/s41375-021-01266-6"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41375-020-0890-1","article-title":"Frequency of infections in 948 MPN patients: A prospective multicenter patient-reported pilot study","volume":"34","author":"Crodel","year":"2020","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106646","DOI":"10.1016\/j.leukres.2021.106646","article-title":"Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN","volume":"110","author":"Kricheldorf","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_37","first-page":"E200","article-title":"Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group","volume":"96","author":"Harnois","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1097\/HS9.0000000000000609","article-title":"Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021","volume":"5","author":"Saunders","year":"2021","journal-title":"HemaSphere"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1038\/s41375-020-01032-0","article-title":"COVID-19 in Philadelphia-negative myeloproliferative disorders: A GIMEMA survey","volume":"34","author":"Breccia","year":"2020","journal-title":"Leukemia"},{"key":"ref_40","unstructured":"Ash Research Collaborative (2021, May 26). COVID-19 Registry. Available online: https:\/\/www.ashresearchcollaborative.org\/s\/covid-19-registry."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100775","DOI":"10.1016\/j.blre.2020.100775","article-title":"When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities","volume":"47","author":"Wang","year":"2021","journal-title":"Blood Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-020-00970-7","article-title":"Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study","volume":"13","author":"Cedillo","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/s41375-021-01143-2","article-title":"Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm","volume":"35","author":"Salisbury","year":"2021","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","article-title":"High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bjh.16956","article-title":"Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date","volume":"190","author":"Iyengar","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41408-021-00509-0","article-title":"Long-term follow-up of recovered MPN patients with COVID-19","volume":"11","author":"Barbui","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Barbui, T., De Stefano, V., Carobbio, A., Iurlo, A., Alvarez-Larran, A., Cuevas, B., Ferrer Mar\u00edn, F., Vannucchi, A.M., Palandri, F., and Harrison, C. (2021). Direct oral anticoagulants for myeloproliferative neoplasms: Results from an international study on 442 patients. Leukemia, 1\u20135.","DOI":"10.1038\/s41375-021-01279-1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"Ruggeri","year":"2016","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(21)00105-8","article-title":"COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year","volume":"8","author":"Leentjens","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.2020006520","article-title":"COVID-19 and coagulation: Bleeding and thrombotic manifestations of SARS-CoV-2 infection","volume":"136","author":"Dzik","year":"2020","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-021-00417-3","article-title":"Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19","volume":"11","author":"Barbui","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: Incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"key":"ref_57","unstructured":"Mesa, R., Alvarez-Larran, A., Harrison, C., Kiladjian, J.J., Rambaldi, A., Tefferi, A., Vannucchi, A., Verstovsek, S., De Stefano, V., and Barbui, T. (2021, May 18). COVID-19 Resources, COVID-19 and Myeloproliferative Neoplasms: Frequently Asked Questions. Version 6.0. American Society of Hematology 2021, January 25. Available online: https:\/\/www.hematology.org\/covid-19\/covid-19-and-myeloproliferative-neoplasms."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: Treatment algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis","volume":"10","author":"Guglielmelli","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bcp.13837","article-title":"Atrial fibrillation and human immunodeficiency virus type-1 infection: A systematic review. Implications for anticoagulant and antiarrhythmic therapy","volume":"85","author":"Pastori","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40256-020-00446-6","article-title":"Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology","volume":"20","author":"Patti","year":"2020","journal-title":"Am. J. Cardiovasc. Drugs Drugs Devices Interv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline","volume":"184","author":"McMullin","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/vox.12930","article-title":"Coronavirus disease 2019 (COVID-19) and decrease in blood donation: Experience of Iranian Blood Transfusion Organization (IBTO)","volume":"115","author":"Mohammadi","year":"2020","journal-title":"Vox Sang."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1213\/ANE.0000000000004844","article-title":"Essential Role of Patient Blood Management in a Pandemic: A Call for Action","volume":"131","author":"Shander","year":"2020","journal-title":"Anesth. Analg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.5694\/mja2.50607","article-title":"Managing haematology and oncology patients during the COVID-19 pandemic: Interim consensus guidance","volume":"212","author":"Weinkove","year":"2020","journal-title":"Med. J. Aust."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Cervantes","year":"2010","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00280-009-0991-z","article-title":"Hydroxyurea and hydroxamic acid derivatives as antitumor drugs","volume":"64","author":"Saban","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Pereira","year":"2012","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjh.13886","article-title":"Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera","volume":"172","author":"Kerguelen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2021.03.006","article-title":"COVID-19 as a mediator of in-terferon deficiency and hyperinflammation: Rationale for the use of JAK1\/2 inhibitors in combination with interferon","volume":"60","author":"Hasselbalch","year":"2021","journal-title":"Cy-Tokine Growth Factor Rev."},{"key":"ref_76","first-page":"1","article-title":"Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease","volume":"26","author":"Zahran","year":"2020","journal-title":"Clin. Appl. Thromb.\/Hemost. Off. J. Int. Acad. Clin. Appl. Thromb.\/Hemost."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"14829","DOI":"10.1038\/s41598-019-51339-x","article-title":"Hydroxyurea alters circulating monocyte subsets and dampens its inflammatory potential in sickle cell anemia patients","volume":"9","author":"Guarda","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_78","first-page":"101","article-title":"Hydroxyurea: Overview of clinical data and antiretroviral and immunomodulatory effects","volume":"4","author":"Lori","year":"1999","journal-title":"Antivir. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41375-020-0953-3","article-title":"How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey","volume":"34","author":"Palandri","year":"2020","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for the treatment of myeloid malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/ehm.11.63","article-title":"A new era for IFN-\u03b1 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms","volume":"4","author":"Hasselbalch","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cytogfr.2020.05.002","article-title":"COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons","volume":"53","author":"Nile","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virol.2004.08.011","article-title":"Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV)","volume":"329","author":"Sainz","year":"2004","journal-title":"Virology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood.2020005992","article-title":"Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic","volume":"135","author":"DeBaun","year":"2020","journal-title":"Blood"},{"key":"ref_86","unstructured":"European Medicines Agency (2021, May 21). COVID-19 Pandemic. Available online: https:\/\/www.ema.europa.eu\/en."},{"key":"ref_87","unstructured":"National Comprehensive Cancer Network (2021, May 21). Recorded Patient Webinar: Myeloproliferative Neoplasms (MPN). Available online: https:\/\/www.nccn.org\/patientresources\/patient-resources\/myeloproliferative-neoplasms-mpn."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): A randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","volume":"97","author":"Griesshammer","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-014-2183-0","article-title":"Ruxolitinib-associated tuberculosis: A case of successful ruxolitinib rechallenge","volume":"94","author":"Palandri","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Colomba, C., Rubino, R., Siracusa, L., Lalicata, F., Trizzino, M., Titone, L., and Tolomeo, M. (2012). Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: A case report. BMC Res. Notes, 5.","DOI":"10.1186\/1756-0500-5-552"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","article-title":"Bilateral toxoplasmosis retinitis associated with ruxolitinib","volume":"369","author":"Goldberg","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"P\u00e1lmason, R., Lind\u00e9n, O., and Richter, J. (2015). Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib. BMC Hematol., 15.","DOI":"10.1186\/s12878-015-0029-1"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jaad.2013.09.035","article-title":"Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment","volume":"70","author":"Tong","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1413918","article-title":"Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib","volume":"374","author":"Zetterberg","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"bcr2014204950","DOI":"10.1136\/bcr-2014-204950","article-title":"Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy","volume":"2014","author":"Lee","year":"2014","journal-title":"BMJ Case Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-015-2532-7","article-title":"Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib","volume":"95","author":"Chen","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","article-title":"Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis?","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: A storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun. Signal. CCS"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fmicb.2019.01057","article-title":"The Role of Interleukin 6 During Viral Infections","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","article-title":"Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: A prospective observational study","volume":"35","author":"Vannucchi","year":"2021","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"687","DOI":"10.7326\/M21-0111","article-title":"SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn","volume":"174","author":"Connors","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_114","first-page":"729","article-title":"COVID-19, SARS and MERS: Are they closely related?","volume":"26","author":"Petrosillo","year":"2020","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014A target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine"},{"key":"ref_117","first-page":"e8871","article-title":"The Potential Vaccine Component for COVID-19: A Comprehensive Review of Global Vaccine Development Efforts","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1056\/NEJMc2101951","article-title":"BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers","volume":"384","author":"Benenson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"326","DOI":"10.15585\/mmwr.mm7009e3","article-title":"Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program\u2014Israel, December 2020\u2013February 2021","volume":"70","author":"Rinott","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers\u2014Eight U.S. Locations, December 2020\u2013March 2021","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_125","unstructured":"Janssen Biotech, Inc. (2021, May 26). FDA Briefing Document. Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. In: Vaccines and Related Biological Products Advisory Committee Meeting, Available online: https:\/\/www.fda.gov\/media\/146217\/download."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford\u2013AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(21)00762-5","article-title":"Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: Side-effect or coincidence?","volume":"397","author":"Schmidt","year":"2021","journal-title":"Lancet"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","article-title":"Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19","volume":"21","author":"Bonaventura","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Sangli, S., Virani, A., Cheronis, N., Vannatter, B., Minich, C., Noronha, S., Bhagavatula, R., Speredelozzi, D., Sareen, M., and Kaplan, R.B. (2021). Thrombosis with Thrombocytopenia After the Messenger RNA-1273 Vaccine. Ann. Intern. Med., 244.","DOI":"10.7326\/L21-0244"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Gresele, P., Momi, S., Marcucci, R., Ramundo, F., De Stefano, V., and Tripodi, A. (2021). Interactions of adenoviruses with platelets and coagulation and the vaccine-associated autoimmune thrombocytopenia thrombosis syndrome. Haematologica, epub ahead of print.","DOI":"10.3324\/haematol.2021.279289"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s11739-021-02793-x","article-title":"Vaccine-induced thrombotic thrombocytopenia: The elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines","volume":"16","author":"Marcucci","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_137","first-page":"n699","article-title":"Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ Clin. Res."},{"key":"ref_138","unstructured":"Marks, P. (2021, May 26). Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. FDA 2021, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Passamonti, F., Romano, A., Salvini, M., Merli, F., Porta, M.G.D., Bruna, R., Coviello, E., Romano, I., Cairoli, R., and Lemoli, R. (2021). COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. Br. J. Haematol., 1\u20137.","DOI":"10.1111\/bjh.17704"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/leu.2016.12","article-title":"Myeloproliferative neoplasms and inflammation: Whether to target the malignant clone or the inflammatory process or both","volume":"30","author":"Koschmieder","year":"2016","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: Guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: Preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Harrington, P., de Lavallade, H., Doores, K.J., O\u2019Reilly, A., Seow, J., Graham, C., Lechmere, T., Radia, D., Dillon, R., and Shanmugharaj, Y. (2021). Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 1\u20135.","DOI":"10.1101\/2021.04.27.21256096"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: A national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Guglielmelli, P., Mazzoni, A., Maggi, L., Kiros, S.T., Zammarchi, L., Pilerci, S., Rocca, A., Spinicci, M., Borella, M., and Bartoloni, A. (2021). Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am. J. Hematol., epub ahead of print.","DOI":"10.1002\/ajh.26305"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Gutwein","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjh.17644","article-title":"Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms","volume":"194","author":"Chowdhury","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_151","unstructured":"Board on Health Care Services, and Institute of Medicine (2012). The Role of Telehealth in an Evolving Health Care Environment: Workshop Summary, National Academies Press."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1370\/afm.2095","article-title":"Patient Perceptions of Telehealth Primary Care Video Visits","volume":"15","author":"Powell","year":"2017","journal-title":"Ann. Fam. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1357633X16686777","article-title":"Effect of telehealth intervention on breast cancer patients\u2019 quality of life and psychological outcomes: A meta-analysis","volume":"24","author":"Chen","year":"2018","journal-title":"J. Telemed. Telecare"},{"key":"ref_154","first-page":"973","article-title":"Telemedicine During the COVID-19 in Italy: A Missed Opportunity?","volume":"26","author":"Omboni","year":"2020","journal-title":"Telemed. J. e-Health Off. J. Am. Telemed. Assoc."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1056\/NEJMp2003539","article-title":"Virtually Perfect? Telemedicine for Covid-19","volume":"382","author":"Hollander","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1056\/NEJMp1710735","article-title":"In-Person Health Care as Option B","volume":"378","author":"Duffy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamainternmed.2018.1314","article-title":"The Role of Telehealth in the Medical Response to Disasters","volume":"178","author":"Lurie","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_158","first-page":"m998","article-title":"Video consultations for covid-19","volume":"368","author":"Greenhalgh","year":"2020","journal-title":"BMJ Clin. Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(20)30424-4","article-title":"Telemedicine 2020 and the next decade","volume":"395","author":"Dorsey","year":"2020","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Kadir, M.A. (2020). Role of telemedicine in healthcare during COVID-19 pandemic in developing countries. Telehealth Med. Today, 5.","DOI":"10.30953\/tmt.v5.187"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjh.16775","article-title":"Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic","volume":"189","author":"Pavord","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bjh.16620","article-title":"Care of haematology patients in a COVID-19 epidemic","volume":"189","author":"Willan","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.17208","article-title":"Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: Selection criteria and patients\u2019 satisfaction","volume":"192","author":"Palandri","year":"2021","journal-title":"Br. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4750\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:03:42Z","timestamp":1760166222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/19\/4750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":163,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13194750"],"URL":"https:\/\/doi.org\/10.3390\/cancers13194750","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,9,23]]}}}